Henkja schreef op 14 februari 2018 23:37:
Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented:
“Shire delivered 8% pro forma product sales growth to $14.4 billion in 2017, an increase of over $1 billion. Of particular note are the strong performance of our Immunology franchise and the significant contribution from recently launched products, as well as growth in international markets. We increased Non GAAP diluted earnings per ADS by 16%, realizing cost synergies ahead of plan.
Dit is in de USA boekhoudkundig toegestaan (GAAP)
Ze hebben circa 1 miljard boekhoudkundig proforma opgevoerd